Capital Fund Management S.A. Grows Stock Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Capital Fund Management S.A. lifted its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 73.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 24,758 shares of the company's stock after acquiring an additional 10,520 shares during the period. Capital Fund Management S.A. owned 0.08% of Medpace worth $8,225,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in MEDP. Invesco Ltd. raised its holdings in shares of Medpace by 91.8% in the fourth quarter. Invesco Ltd. now owns 1,084,753 shares of the company's stock worth $360,387,000 after buying an additional 519,186 shares during the period. Proficio Capital Partners LLC boosted its stake in shares of Medpace by 34,497.4% during the fourth quarter. Proficio Capital Partners LLC now owns 242,528 shares of the company's stock valued at $80,575,000 after purchasing an additional 241,827 shares during the period. Raymond James Financial Inc. bought a new position in shares of Medpace in the fourth quarter worth about $78,144,000. Norges Bank purchased a new position in Medpace in the 4th quarter worth about $69,859,000. Finally, GW&K Investment Management LLC lifted its holdings in Medpace by 93.9% during the 4th quarter. GW&K Investment Management LLC now owns 275,460 shares of the company's stock valued at $91,516,000 after buying an additional 133,379 shares in the last quarter. 77.98% of the stock is owned by institutional investors.

Medpace Stock Performance

MEDP stock traded down $0.22 during trading on Friday, reaching $296.28. The company had a trading volume of 698,291 shares, compared to its average volume of 325,409. Medpace Holdings, Inc. has a twelve month low of $272.00 and a twelve month high of $459.77. The company has a market cap of $8.96 billion, a price-to-earnings ratio of 23.46, a price-to-earnings-growth ratio of 3.81 and a beta of 1.46. The firm has a 50-day simple moving average of $319.15 and a 200-day simple moving average of $333.57.

Medpace (NASDAQ:MEDP - Get Free Report) last released its earnings results on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. Sell-side analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. Mizuho decreased their price target on shares of Medpace from $400.00 to $355.00 and set an "outperform" rating for the company in a research note on Wednesday, April 9th. TD Cowen cut Medpace from a "buy" rating to a "hold" rating and lowered their target price for the stock from $370.00 to $328.00 in a report on Monday. Leerink Partners initiated coverage on Medpace in a research note on Monday, March 24th. They set a "market perform" rating and a $330.00 price target on the stock. Leerink Partnrs raised shares of Medpace to a "hold" rating in a research note on Monday, March 24th. Finally, Truist Financial reduced their price target on shares of Medpace from $347.00 to $333.00 and set a "hold" rating for the company in a report on Thursday, April 10th. Ten analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, Medpace currently has an average rating of "Hold" and an average target price of $357.50.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.